Bymetric
UK company intelligence
Company Active PRIVATE-LIMITED-GUARANT-NSC

Company profile

Beatson Institute For Cancer Research

UK company SC084170, incorporated on 3 August 1983.

Home

Beatson Institute For Cancer Research is a UK company with status Active founded in 1983.

Company number
SC084170
Incorporated
3 Aug 1983
Companies House status
Active

Company identity

Founded / incorporated
3 August 1983

Company number SC084170

Verify at Companies House
Legal name
BEATSON INSTITUTE FOR CANCER RESEARCH
Company type
PRI/LTD BY GUAR/NSC (Private, limited by guarantee, no share capital)
Region
Unknown
Registered address
GARSCUBE ESTATE
SWITCHBACK ROAD
BEARSDEN
GLASGOW
G61 1BD
Insolvency history
No

Corporate ownership

Updated 07 Jul 2026 09:49

1 level 1 ultimate controller Controls 1
1
Company Active PRIVATE-LIMITED-GUARANT-NSC
Beatson Institute For Cancer Research
CRN SC084170
2
Direct and ultimate controller Active PRIVATE-LIMITED-GUARANT-NSC-LIMITED-EXEMPTION
Cancer Research UK
CRN 04325234

Company events

Reference milestones and recent Companies House filing stream events.

5 events
31 Dec
2026

Accounts due

Accounts Due

Next accounts due date

24 Dec
2026

Confirmation statement due

Confirmation Due

Next confirmation statement due date

10 Dec
2025

Confirmation statement filed

Confirmation

Last confirmation statement made up date

31 Mar
2025

Accounts filed

Accounts

Last accounts made up date

03 Aug
1983

Incorporated

Inception

Company registered at Companies House

Public funding

1 award
First funded
2023
Funded years
2023
Age at first award
39 years

Projects

2023 Collaborative R&D

Project LIPICARE - Combining nanotechnology, gene editing and CAR-T to create a 'one-shot' cure for cancer

1 Feb 2023 to 31 Jan 2026

Awarded
£0
Total cost £0

LIPICARE is a bold and ambitious project conceived by a consortium of the UK's leading scientists in the field of gene and cancer therapy. We aim to combine advances in nanotechnology, cell therapy and gene editing to create a one-shot cure for cancer. Chimeric Antigen Receptor -- T cell (CAR-T) cancer immunotherapy involves genetically manipulating immun...

Product types

Collaborative R&D